Abdollah Firas, Suardi Nazareno, Capitanio Umberto, Matloob Rayan, Fossati Nicola, Castiglione Fabio, Di Trapani Ettore, Di Trapani Dario, Russo Andrea, Carenzi Cristina, Montorsi Francesco, Rigatti Patrizio, Bertini Roberto
Department of Urology, URI-Urological Research Institute, San Raffaele Hospital, University Vita-Salute, Milan, Italy.
Department of Urology, URI-Urological Research Institute, San Raffaele Hospital, University Vita-Salute, Milan, Italy.
Urol Oncol. 2014 Jan;32(1):43.e9-16. doi: 10.1016/j.urolonc.2013.05.006. Epub 2013 Aug 2.
In surgically treated patients with renal cell carcinoma (RCC), the progression-free survival (PFS) rate may significantly change according to the progression-free postoperative period. To test this hypothesis, we set to evaluate the conditional PFS rate in surgically treated patients with RCC.
We evaluated 1,454 patients with RCC, surgically treated between 1987 and 2010, at a single institution. Cumulative survival estimates were used to generate conditional PFS rates. Separate Cox regression models were fitted to predict clinical-progression risk in patients who were progression free from 1 to 10 years after surgery.
During the immediate postoperative period, the 5-year PFS rate was 88%, and it increased to 92%, 94%, and 97% in patients who remained progression free at, respectively, 1, 5, and 10 years after surgery. At multivariable analyses, where patients with stage I disease were considered as a reference, the highest clinical-progression risk was observed at the eighth postoperative year in patients with stage II disease (hazard ratio [HR]: 2.9) and during the immediate postoperative period in patients with stage III to IV disease (HR: 5.5). In comparison with patients with grade I disease, the highest clinical-progression risk was observed at the fourth (as well as eighth) postoperative year in patients with grade II disease (HR: 5.7), sixth postoperative year in patients with grade III disease (HR: 7.2), and during the immediate postoperative period in patients with grade IV disease (HR: 8.5).
The postoperative progression-free period has an important effect on the subsequent clinical-progression risk. This aspect should be considered along with tumor characteristics to plan the most cost-effective follow-up scheme for surgically treated patients with RCC.
在接受手术治疗的肾细胞癌(RCC)患者中,无进展生存期(PFS)率可能会根据术后无进展期而显著变化。为验证这一假设,我们着手评估接受手术治疗的RCC患者的条件性PFS率。
我们评估了1987年至2010年间在单一机构接受手术治疗的1454例RCC患者。采用累积生存估计值来生成条件性PFS率。拟合单独的Cox回归模型以预测术后1至10年无进展患者的临床进展风险。
在术后即刻,5年PFS率为88%,在术后1年、5年和10年仍无进展的患者中,该率分别升至92%、94%和97%。在多变量分析中,以I期疾病患者作为参照,II期疾病患者在术后第8年观察到最高临床进展风险(风险比[HR]:2.9),III至IV期疾病患者在术后即刻观察到最高临床进展风险(HR:5.5)。与I级疾病患者相比,II级疾病患者在术后第4年(以及第8年)观察到最高临床进展风险(HR:5.7),III级疾病患者在术后第6年观察到最高临床进展风险(HR:7.2),IV级疾病患者在术后即刻观察到最高临床进展风险(HR:8.5)。
术后无进展期对后续临床进展风险有重要影响。在为接受手术治疗的RCC患者规划最具成本效益的随访方案时,应结合肿瘤特征考虑这一方面。